Comparable Autoantibody Serum Levels against Amyloid- and Inflammation-Associated Proteins in Parkinson’s Disease Patients and Controls

Abstract

Naturally occurring autoantibodies (NAbs) against a number of potentially disease-associated cellular proteins, including Amyloid-beta1–42 (Abeta1–42), Alpha-synuclein (Asyn), myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), and S100 calcium binding protein B (S100B) have been suggested to be associated with neurodegenerative disorders, in particular Alzheimer’s (AD) and Parkinson’s disease (PD). Whereas the (reduced) occurrence of specific NAbs in AD is widely accepted, previous literature examining the relation of these NAb titres between PD patients and controls, as well as comparing these levels with demographic and clinical parameters in PD patients have produced inconsistent findings. We therefore aimed, in a cross-sectional approach, to determine serum titres of the above NAbs in a cohort of 93 PD patients (31 of them demented) and 194 controls. Levels were correlated with demographic and clinical variables, cerebrospinal fluid Abeta1–42, total tau and phospho-tau levels, as well as with single nucleotide polymorphisms (SNPs) of genes which either have been reported to influence the immune system, the amyloid cascade or the occurrence of PD (ApoE, GSK3B, HLA-DRA, HSPA5, SNCA, and STK39). The investigated NAb titres were neither significantly associated with the occurrence of PD, nor with demographic and clinical parameters, neurodegenerative markers or genetic variables. These results argue against a major potential of blood-borne parameters of the adaptive immune system to serve as trait or state markers in PD.

Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia

“…In contrast, the level of nAbs-αS was unchanged between the two study subgroups. Our findings are consistent with previous results from a study by Maetzler et al, who also did not observe differences in the serum level of nAbs-αS between PDND and PDD patients [26]. In addition, we identified nAbs-tau as less avid than the other investigated nAbs.…”

Clinical correlation of peripheral CD4+-cell sub-sets, their imbalance and Parkinson's disease

“…These immune-associated types of inflammation exist not only in the brain (7,8), but the peripheral immune system is also thought to contribute to the onset and progression of the neurodegenerative process in PD (9)(10)(11)(12). Inflammation in the peripheral immune system is hypothesized to contribute to the onset and progression of the neurodegenerative process observed in PD, due to serum αSYN-specific antibodies (10), and lymphocyte infiltration into the brains of patients with PD (7). In light of these studies, it is indicated that the function of immune cells is essential during inflammation-induced PD.…”

Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson’s disease

“…Many risk factors of PD such as aging 7 and environmental toxins 8 are likely to contribute to the pathogenesis of PD by initiating chronic changes throughout the body. Subsequent alterations in energy metabolism, oxidative stress, inflammation, and corticosteroid signaling occur that could further contribute to the development of PD 9 10 11 . Given the effective interventions for delaying or preventing the loss of dopaminergic neurons in PD patients 12 , early identification of individuals at risk is particularly crucial.…”